Clinical significance of anaemia in chronic hepatitis c on the combined antiviral therapy with pegylated

Abstract

In order to study the effect of combination antiviral therapy for hemoglobin and red blood cells in patients with chronic hepatitis C were estimated absolute numbers of red blood parameters. To determine the relation between the content of red blood cells and hemoglobin at different stages of antiviral therapy with the initial clinical and laboratory parameters (gender, age, body mass index, genotype, level of viremia, ALT, fibrosis), as well as the results of combined antiviral therapy. Established that the decrease in hemoglobin levels were observed more frequently than the decline in the number of erythrocytes (63,6% and 21,1% respectively). In addition, anemia that occurred during treatment of HCV patients with pegylated interferon-α, directly correlated with the rate of sustained virological response. The study established prognostic criteria, indicating the possible development of anemia in the background of anti-viral therapy: the female sex, BMI <20 kg/m2, 1 genotype of HCV.

Keywords

• chronic hepatitis c
• antiviral therapy
• interferon-α
• ribavirin
• side effects
• anemia
• red blood cells and hemoglobin